Adverum Biotechnologies to Present at Upcoming Investor Conferences
Cowen and Company 37th AnnualHealth Care Conference
Date:Monday, March 6, 2017
Time:2:40pm ET
Location:Boston, MA - 29th Annual
ROTH Conference
Date:Monday, March 13, 2017
Time:7:30am PT
Location:Laguna Niguel, CA
The audio portions of the corporate presentations will be accessible live through the investors’ section of the Company’s website at www.adverum.com. A replay will be available for 14 days following the presentations.
About
Adverum is a gene therapy company committed to discovering and developing novel medicines that can offer life-changing benefits to patients living with rare diseases or diseases of the eye who currently have limited or burdensome treatment options. Adverum has a robust pipeline that includes product candidates to treat wet age-related macular degeneration (wAMD), alpha-1 antitrypsin (A1AT) deficiency, and hereditary angioedema (HAE). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with
Contact for Adverum:Leone Patterson Chief Financial OfficerAdverum Biotechnologies, Inc. 650-665-7222 lpatterson@adverum.comJill Steier Senior Vice PresidentThe Trout Group LLC 646-378-2946 jsteier@troutgroup.com